[go: up one dir, main page]

IL71143A - 2,2-difluoro nucleosides,their preparation and pharmaceutical compositions comrising them - Google Patents

2,2-difluoro nucleosides,their preparation and pharmaceutical compositions comrising them

Info

Publication number
IL71143A
IL71143A IL71143A IL7114384A IL71143A IL 71143 A IL71143 A IL 71143A IL 71143 A IL71143 A IL 71143A IL 7114384 A IL7114384 A IL 7114384A IL 71143 A IL71143 A IL 71143A
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
nucleosides
difluoro
comrising
Prior art date
Application number
IL71143A
Other languages
English (en)
Other versions
IL71143A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23881409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL71143(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to IL80463A priority Critical patent/IL80463A/xx
Publication of IL71143A0 publication Critical patent/IL71143A0/xx
Publication of IL71143A publication Critical patent/IL71143A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
IL71143A 1983-03-10 1984-03-04 2,2-difluoro nucleosides,their preparation and pharmaceutical compositions comrising them IL71143A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL80463A IL80463A (en) 1983-03-10 1984-03-04 2-desoxy-2,2-difluoro-furanose derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/473,883 US4526988A (en) 1983-03-10 1983-03-10 Difluoro antivirals and intermediate therefor

Publications (2)

Publication Number Publication Date
IL71143A0 IL71143A0 (en) 1984-06-29
IL71143A true IL71143A (en) 1988-07-31

Family

ID=23881409

Family Applications (2)

Application Number Title Priority Date Filing Date
IL71143A IL71143A (en) 1983-03-10 1984-03-04 2,2-difluoro nucleosides,their preparation and pharmaceutical compositions comrising them
IL80463A IL80463A (en) 1983-03-10 1984-03-04 2-desoxy-2,2-difluoro-furanose derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL80463A IL80463A (en) 1983-03-10 1984-03-04 2-desoxy-2,2-difluoro-furanose derivatives

Country Status (36)

Country Link
US (5) US4526988A (fr)
EP (1) EP0122707B1 (fr)
JP (2) JPS59175498A (fr)
KR (1) KR860001283B1 (fr)
AR (1) AR243533A1 (fr)
AT (1) ATE29726T1 (fr)
AU (1) AU565856B2 (fr)
BG (1) BG40814A3 (fr)
CA (2) CA1218647A (fr)
CS (1) CS246075B2 (fr)
CY (1) CY1489A (fr)
DD (1) DD216468A5 (fr)
DE (2) DE19675003I2 (fr)
DK (2) DK162529C (fr)
ES (1) ES8602840A1 (fr)
FI (1) FI77870C (fr)
GB (2) GB2136425B (fr)
GR (1) GR81845B (fr)
HK (1) HK44989A (fr)
HU (1) HU193893B (fr)
IE (1) IE57071B1 (fr)
IL (2) IL71143A (fr)
KE (1) KE3874A (fr)
LU (1) LU88791I2 (fr)
MX (1) MX9203246A (fr)
MY (1) MY102025A (fr)
NL (1) NL950018I2 (fr)
NZ (1) NZ207358A (fr)
PH (2) PH23240A (fr)
PL (1) PL142437B1 (fr)
PT (1) PT78181B (fr)
RO (1) RO89963A (fr)
SG (1) SG21889G (fr)
SU (1) SU1442076A3 (fr)
UA (1) UA5955A1 (fr)
ZA (1) ZA841605B (fr)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
CA1295998C (fr) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides et leur utilisation en tant qu'agents antineoplasiques
US4681873A (en) * 1985-07-29 1987-07-21 Warner-Lambert Company 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
EP0277599A3 (fr) * 1987-01-30 1990-05-09 Asahi Glass Company Ltd. Dérivés de cyclopentane contenant du fluor et procédés pour leur préparation
CA1340645C (fr) * 1987-04-17 1999-07-13 Victor E. Marquez Didesoxynucleosides stables en milieu acide, actifs contre les effets cytopathiques du virus de l'immunoeficience humaine
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0688782B1 (fr) 1987-08-28 2002-05-02 Eli Lilly And Company Procédé stéréosélectif pour préparer 2',2'-difluorolactonen protégés
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
ES2075040T3 (es) * 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
CA1339964C (fr) * 1988-03-16 1998-07-21 Dennis A. Carson Derives de substitution de l'adenine, utiles comme agents therapeutiques
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US4954623A (en) * 1989-03-20 1990-09-04 Eli Lilly And Company Recovery of difluoro sugar
CA2012129A1 (fr) * 1989-03-20 1990-09-20 Ramakrishnan Nagarajan Recuperation de sucre difluore
US5256797A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5256798A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401861A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DE69308400T2 (de) * 1992-06-22 1997-07-10 Lilly Co Eli Verfahren zur Stereoselektivanionglycosylierung
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5252756A (en) * 1992-06-22 1993-10-12 Eli Lilly And Company Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
MX9303713A (es) * 1992-06-22 1994-05-31 Lilly Co Eli Proceso estereoselectivo para preparar un derivadoribofuranosilo enriquecido con alfa anomero.
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5428176A (en) * 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
US5633367A (en) * 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
CA2171518A1 (fr) * 1995-03-24 1996-09-25 Douglas Patton Kjell Methode de preparation de 2,2'-anhydro- et 2' -ceto-1-(3',5'-di-o-protege-.beta.-d-arabinofuranosyl)nucleosides
AU1289697A (en) 1995-12-13 1997-07-03 Eli Lilly And Company Alpha, alpha-difluoro-beta-hydroxy thiol esters and their synthesis
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US5808020A (en) * 1996-08-12 1998-09-15 Associated Universities, Inc. Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
US6013790A (en) * 1996-09-25 2000-01-11 Board Of Regents University Of Nebraska-Lincoln Heavily fluorinated sugar analogs
WO1998042351A1 (fr) * 1997-03-24 1998-10-01 Eli Lilly And Company Acides difluoronucleosides-phosphoniques et leurs derives
DK1058686T3 (da) 1998-02-25 2007-03-05 Univ Emory 2'-fluornukleosider
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR100589032B1 (ko) * 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002365256A1 (en) * 2001-10-25 2003-07-30 Eli Lilly And Company Gemcitabine in the treatment of smallpox
EP1465615B1 (fr) * 2002-01-15 2012-08-01 Trustees of Dartmouth College Derives de bis- enone tricyclique et methodes d'utilisation
WO2003068162A2 (fr) * 2002-02-14 2003-08-21 Pharmasset Ltd. Analogues de nucleoside fluores modifies
EP1604665B1 (fr) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. Inhibiteur de kinase c-kit
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
US20080026045A1 (en) * 2003-05-20 2008-01-31 Jonathan Lewis Combination Chemotherapy Comprising a Gemcitabine and a Liposomal Platium Complex
PT2604620T (pt) * 2003-05-30 2016-08-18 Gilead Pharmasset Llc Analogos de nucleósido fluorados modificados
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
WO2005044788A1 (fr) * 2003-11-11 2005-05-19 Eisai Co., Ltd. Derive d'uree et son procede de production
ES2389809T3 (es) * 2004-02-06 2012-10-31 Threshold Pharmaceuticals, Inc. Terapias anticancerosas
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
EP2348029A1 (fr) * 2004-07-21 2011-07-27 Pharmasset, Inc. Preparation de pyrimidines et purines 2-desoxy-2-fluoro-d-ribofuranosyl substitues en alkyle et leurs dérives
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
BRPI0513783A (pt) * 2004-07-29 2008-05-13 Hanmi Pharm Ind Co Ltd derivados 1-(alfa)-halo-2, 2-diflúor-2-desóxi-d-ribofuranose e processo para a sua preparação
EP1812457A1 (fr) * 2004-07-30 2007-08-01 Pharmaessentia Corp. SYNTHÈSE STÉRÉOSÉLECTIVE DE ß-NUCLÉOSIDES
EP1809301B1 (fr) * 2004-09-14 2019-11-06 Gilead Pharmasset LLC Intermédiaires de d-ribonolactone à substitution 2-fluoro-2-alkyl
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
CA2586687A1 (fr) * 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides et procede de preparation de ceux-ci
PT1831237E (pt) * 2004-12-17 2008-09-22 Lilly Co Eli Pró-fármaco amida da gemcitabina, suas composições e utilizações
JP5475234B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
ES2341663T3 (es) * 2005-03-04 2010-06-24 Fresenius Kabi Oncology Limited Intermedio y procedimiento para preparar 2'-desoxi-2',2'-difluoro-d-ribofuranosil nucleosidos enriquecidos en el anomero beta.
US7485716B2 (en) * 2005-05-02 2009-02-03 Pharmaessentia Corp. Stereoselective synthesis of β-nucleosides
EP1891087A4 (fr) * 2005-06-03 2008-07-30 Scinopharm Taiwan Ltd Procede de fabrication d'un 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate enrichi en alpha-anomere, et son utilisation pour la fabrication d'un beta nucleoside
AU2011202539B2 (en) * 2005-06-03 2012-07-05 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
CN101242822B (zh) 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
AT502221A1 (de) * 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (fr) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
WO2007015257A2 (fr) * 2005-08-04 2007-02-08 Hetero Drugs Limited Procede de preparation de gemcitabine utilisant de nouveaux intermediaires
WO2007026864A1 (fr) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. Procédé de préparation de composition pharmaceutique ayant une meilleure capacite de désintégration
EP1940859A1 (fr) 2005-10-28 2008-07-09 Arch Pharmalabs Limited Procede ameliore de preparation de gemcitabine hydrochlorure
WO2007052849A1 (fr) * 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. Utilisation d'une combinaison de substance anti-angiogenique et d'inhibiteur de kinase c-kit
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
BRPI0619928A2 (pt) * 2005-12-14 2011-10-25 Dong A Pharm Co Ltd processo de produção de 2', 2'-difluornucleosìdeo e intermediário
EP1994042A4 (fr) * 2006-02-06 2009-03-18 Reddys Lab Ltd Dr Préparation de gemcitabine
CA2641719A1 (fr) * 2006-02-07 2007-08-16 Chemagis Ltd. Procede de preparation de gemcitabine et de produits intermediaires associes
US20070249823A1 (en) * 2006-04-20 2007-10-25 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
CN104706637A (zh) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
KR100741310B1 (ko) * 2006-08-01 2007-08-01 (주) 유일팜테크 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
KR101472600B1 (ko) * 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
WO2008033466A2 (fr) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions et procédés pour le traitement de maladies virales
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (fr) 2006-10-12 2018-09-19 Astex Therapeutics Limited Combinaisons pharmaceutiques
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CA2670099A1 (fr) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthese et activites biologiques de nouveaux composes tricycliques-bis-enones (tbe)
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
KR20090108086A (ko) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
JP5319306B2 (ja) * 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
EP2139884B1 (fr) * 2007-03-23 2013-12-04 Dongwoo Syntech Co., Ltd. Procédé de préparation de la 2'-désoxy-2',2'-difluorocytidine
CN101024667B (zh) * 2007-03-30 2011-01-26 湖北益泰药业有限公司 盐酸吉西他宾的合成方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
CN100475832C (zh) * 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
WO2009023845A2 (fr) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Thérapie combinatoire avec triterpénoïdes synthétiques et gemcitabine
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
US20090069354A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
WO2009042064A2 (fr) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Conjugués nucléoside phosphate oligomères
JP4253357B1 (ja) 2007-09-27 2009-04-08 株式会社湯山製作所 手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2009061894A1 (fr) * 2007-11-06 2009-05-14 Pharmaessentia Corporation Nouveau procédé de synthèse de nucléosides bêta
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CN101918030B (zh) 2007-11-09 2015-10-14 派瑞格恩医药公司 抗vegf抗体的组合物和方法
EP2217244A4 (fr) * 2007-11-12 2011-08-31 Bipar Sciences Inc Traitement du cancer de l'utérus et du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
RS58486B1 (sr) * 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
CA2713930A1 (fr) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Utilisation combinee d'un inhibiteur de l'angiogenese et d'un taxane
NZ588710A (en) 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
EP2279197B1 (fr) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Modulateurs d'inflammation antioxydants: dérivés d'acide oléanolique présentant une saturation dans l'anneau c
US7943778B2 (en) * 2008-04-18 2011-05-17 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US8258329B2 (en) 2008-04-18 2012-09-04 Reata Pharmaceuticals, Inc. Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8350023B2 (en) * 2008-06-12 2013-01-08 ScnioPharm Taiwan, Ltd. Crystalline polymorphs of gemcitabine base
JP5758801B2 (ja) 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ 単環式シアノエノンおよびその使用方法説明
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010049947A2 (fr) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Préparation de gemcitabine et de ses intermédiaires
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
AU2010234637B2 (en) * 2009-04-06 2016-05-12 Otsuka Pharmaceutical Co., Ltd. (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
WO2010118010A1 (fr) * 2009-04-06 2010-10-14 Eisai Inc. Association de décitabine et d'un inhibiteur de la cytidine désaminase et utilisation de cette association dans le traitement du cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US20120129799A1 (en) 2009-07-31 2012-05-24 Astron Research Limited stable composition of ready-to-use gemcitabine injection
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2536720A1 (fr) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de kinases
EP2547359B1 (fr) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibiteurs des interactions de liaison de sous unité alpha d'intégrine à-de protéine g
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
WO2011143590A1 (fr) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Compositions et méthodes de polythérapie utilisant dérivés d'acide lipoïque et agent antiprolifératif
WO2011143593A1 (fr) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugués de dérivé d'acide lipoïque et d'agent antiprolifératif et leurs utilisations médicales
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
WO2012069972A1 (fr) 2010-11-19 2012-05-31 Piramal Life Sciences Limited Combinaison pharmaceutique pour le traitement du cancer du sein
EP2646453A1 (fr) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Composés
WO2012087943A2 (fr) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibiteurs de l'interaction de liaison entre le récepteur du facteur de croissance épidermique et la protéine de choc thermique 90
CN102153602B (zh) * 2011-02-24 2013-11-06 中国农业大学 呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
CN102153601A (zh) * 2011-02-26 2011-08-17 湖南欧亚生物有限公司 一种高选择性的制备盐酸吉西他滨以及其中间体的方法
WO2012123889A1 (fr) 2011-03-14 2012-09-20 Piramal Healthcare Limited Combinaison pharmaceutique synergique pour le traitement du cancer du pancréas
KR20140025434A (ko) 2011-04-01 2014-03-04 제넨테크, 인크. Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
US8765933B2 (en) 2011-04-07 2014-07-01 Pharmaessentia Corp. Asynthesis of β-nucleosides
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
JP2014511875A (ja) 2011-04-13 2014-05-19 メルク・シャープ・アンド・ドーム・コーポレーション ２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法
EP2697242B1 (fr) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
CN102453064B (zh) * 2011-06-30 2014-07-09 江苏豪森药业股份有限公司 制备吉西他滨盐酸盐的方法
EP2731434A4 (fr) 2011-07-13 2014-12-31 Merck Sharp & Dohme Dérivés de nucléosides 5'-substitués et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013009737A1 (fr) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. Analogues de nucléosides 5'-substitués et leurs procédés d'utilisation pour le traitement de maladies virales
DK3311827T3 (da) 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
CN102417533A (zh) * 2011-10-28 2012-04-18 江苏正大清江制药有限公司 盐酸吉西他滨的合成方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NO2755614T3 (fr) 2012-01-03 2018-03-31
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (fr) 2012-03-22 2015-10-28 Alios Biopharma Inc Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
EA031986B1 (ru) 2012-04-04 2019-03-29 Галозим, Инк. Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
MX355708B (es) 2012-05-22 2018-04-27 Idenix Pharmaceuticals Llc Compuestos de d-aminoacidos para enfermedades del higado.
CA2871359A1 (fr) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Selectivite mutante et associations d'un inhibiteur de phospho-inositide 3 kinase et agents chimiotherapeutiques pour le traitement du cancer
CN104428006B (zh) 2012-07-04 2017-09-08 弗·哈夫曼-拉罗切有限公司 共价连接的抗原‑抗体缀合物
EP2711008A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine destiné à être utilisé dans le traitement ou la prévention du cancer du sein primitif et métastatique
EP2711007A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine destiné à être utilisé dans le traitement ou la prévention du cancer du sein et de la prostate primitif et métastatique
EP2711009A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Composés destinés à être utilisés dans le traitement ou la prévention du cancer primitif et métastatique du sein et de la prostate
EP2906579B1 (fr) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. Analogues de nucléosides 2'-chloro pour traiter une infection par le virus de l'hépatite c
EP2919759A4 (fr) 2012-11-14 2016-07-20 Ohio State Innovation Foundation Matières et procédés utiles pour le traitement du glioblastome
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
WO2014163558A1 (fr) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticules, constituées de stérol et de saponine de quillaja saponaria molina, leur procédé de préparation et leur utilisation comme support pour des molécules amphipathiques ou hydrophobes dans le domaine médical, notamment pour le traitement du cancer, et composés alimentaires
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
WO2015003747A1 (fr) * 2013-07-10 2015-01-15 Asteriapharma Gmbh Composition contenant des dérivés modifiés d'un antimétabolite de la cytidine pour le traitement d'une maladie sensible
EP3024490A1 (fr) 2013-07-26 2016-06-01 Threshold Pharmaceuticals, Inc. Traitement d'un cancer du pancréas au moyen d'une combinaison d'un promédicament activé par l'hypoxie et d'un taxane
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
SG11201602614XA (en) 2013-10-29 2016-05-30 Otsuka Pharma Co Ltd Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
WO2015191576A1 (fr) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Traitement combiné comprenant un promédicament liposomal de la mitomycine c et une radiothérapie
BR112016029935A2 (pt) 2014-06-26 2017-10-31 Hoffmann La Roche ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
WO2016123143A1 (fr) 2015-01-26 2016-08-04 The University Of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
US20180044368A1 (en) * 2015-02-25 2018-02-15 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
JP6743135B2 (ja) 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
CN108135920A (zh) * 2015-10-05 2018-06-08 努卡那有限公司 组合疗法
LT3386998T (lt) 2015-12-11 2022-01-25 NuCana plc Fosfato darinių ir gemcitabino provaisto nuc-1031 diastereoselektyvi sintezė
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
CN110248673A (zh) 2016-11-21 2019-09-17 百祥制药公司 用于治疗胰腺癌的包括SapC-DOPS的联合疗法
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
PE20200010A1 (es) 2017-04-03 2020-01-06 Hoffmann La Roche Anticuerpos que se unen a steap-1
WO2018200859A1 (fr) 2017-04-26 2018-11-01 Kalman Thomas I Dérivés de nucléoside multicibles
CN111246883A (zh) 2017-08-07 2020-06-05 美国安进公司 用抗pd-l1抗体和溶瘤病毒治疗三阴性乳癌或结肠直肠癌伴随肝转移
BR112020005196A2 (pt) 2017-09-18 2020-09-15 The Regents Of The University Of California anticorpos claudin6 e métodos para tratar câncer
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
EP3737376B1 (fr) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Inhibiteurs sélectifs d'histone déacétylase pour le traitement de maladies humaines
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020044252A1 (fr) 2018-08-31 2020-03-05 Novartis Ag Régimes posologiques pour anticorps anti-m-csf et utilisations associées
EP3669890A1 (fr) 2018-12-18 2020-06-24 Croda International PLC Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
AU2020207026A1 (en) 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
EP3941946B1 (fr) 2019-03-20 2024-12-25 The Regents of the University of California Anticorps anti-claudine-6 et conjugués de médicaments
CN114206934A (zh) 2019-03-20 2022-03-18 加利福尼亚大学董事会 密封蛋白-6双特异性抗体
EP3962945A1 (fr) 2019-04-30 2022-03-09 Instituto de Medicina Molecular João Lobo Antunes Inhibiteurs de la voie rank en combinaison avec des inhibiteurs de cdk
WO2020263793A1 (fr) 2019-06-24 2020-12-30 Amgen Inc. Inhibition de la sirp-gamma pour le traitement du cancer
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN115605492A (zh) 2020-04-21 2023-01-13 配体制药股份有限公司（Us） 核苷酸前药化合物
WO2025019361A1 (fr) 2023-07-14 2025-01-23 Modulation Therapeutics, Inc. Inhibiteurs de scd1 pour le traitement de néoplasmes hématolymphoïdes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
FR1362039A (fr) * 1963-04-17 1964-05-29 Ct D Etudes Experimentales Et Nouveau procédé de préparation du semi-aldéhyde succinique
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4352795A (en) * 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
FR2531962B1 (fr) * 1982-08-17 1986-11-14 Sandoz Sa Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
CA1295998C (fr) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides et leur utilisation en tant qu'agents antineoplasiques

Also Published As

Publication number Publication date
GB8610648D0 (en) 1986-06-04
GB2136425A (en) 1984-09-19
IL80463A0 (en) 1987-01-30
FI77870C (fi) 1989-05-10
HK44989A (en) 1989-06-09
NL950018I2 (nl) 1997-03-03
PL246601A1 (en) 1985-08-13
DK190590D0 (da) 1990-08-10
IE840584L (en) 1984-09-10
EP0122707A1 (fr) 1984-10-24
CY1489A (en) 1989-12-08
FI840890A0 (fi) 1984-03-06
CS246075B2 (en) 1986-10-16
DK170647B1 (da) 1995-11-20
CA1218647A (fr) 1987-03-03
DE3466224D1 (en) 1987-10-22
KE3874A (en) 1989-06-30
PH23240A (en) 1989-06-06
ZA841605B (en) 1985-10-30
HU193893B (en) 1987-12-28
IL71143A0 (en) 1984-06-29
GB2172287B (en) 1987-05-20
AU565856B2 (en) 1987-10-01
DK190590A (da) 1990-08-10
NL950018I1 (fr) 1995-11-01
FI840890A (fi) 1984-09-11
ES530364A0 (es) 1985-12-01
US4526988A (en) 1985-07-02
DK114484A (da) 1984-09-11
JPH06102655B2 (ja) 1994-12-14
CA1223869A (fr) 1987-07-07
JPH0542438B2 (fr) 1993-06-28
PT78181B (en) 1986-08-05
SU1442076A3 (ru) 1988-11-30
SG21889G (en) 1989-07-14
KR840007883A (ko) 1984-12-11
ATE29726T1 (de) 1987-10-15
PT78181A (en) 1984-04-01
DK114484D0 (da) 1984-02-28
MY102025A (en) 1992-02-29
AU2537484A (en) 1984-09-13
US4692434A (en) 1987-09-08
JPH069602A (ja) 1994-01-18
UA5955A1 (uk) 1994-12-29
US5015743A (en) 1991-05-14
DK162529B (da) 1991-11-11
GB2136425B (en) 1987-05-13
GB2172287A (en) 1986-09-17
AR243533A1 (es) 1993-08-31
BG40814A3 (en) 1987-02-16
US5118820A (en) 1992-06-02
RO89963A (fr) 1986-09-30
DE19675003I2 (de) 2003-05-22
DD216468A5 (de) 1984-12-12
GB8405805D0 (en) 1984-04-11
PH23593A (en) 1989-09-11
GR81845B (fr) 1984-12-12
MX9203246A (es) 1992-07-31
NZ207358A (en) 1987-03-06
IE57071B1 (en) 1992-04-22
IL80463A (en) 1988-07-31
ES8602840A1 (es) 1985-12-01
LU88791I2 (fr) 1996-11-05
FI77870B (fi) 1989-01-31
DK162529C (da) 1992-03-30
JPS59175498A (ja) 1984-10-04
KR860001283B1 (ko) 1986-09-05
EP0122707B1 (fr) 1987-09-16
US4808614A (en) 1989-02-28
PL142437B1 (en) 1987-10-31

Similar Documents

Publication Publication Date Title
IL71143A (en) 2,2-difluoro nucleosides,their preparation and pharmaceutical compositions comrising them
DE3468030D1 (en) 13-alpha-alkyl gonanes, their preparation and pharmaceutical compositions containing them
IL66099A0 (en) N-aryl-piperazinealkanamides,their preparation and pharmaceutical compositions containing them
IL73706A0 (en) 2,2'-iminobisethanol derivatives,their preparation and pharmaceutical compositions containing them
IL65076A (en) 3,4-dihydro-5h-2,3-benzo-diazepine derivatives,their preparation and pharmaceutical compositions containing them
IL70756A (en) 3-amino-pyridazine derivatives,their preparation and pharmaceutical compositions containing them
IL73951A0 (en) 2-phenyl-imidazoles,their preparation and pharmaceutical compositions containing them
IL71475A (en) N-aryl-alpha-amino-carboxamides,their preparation and pharmaceutical compositions containing them
IL66683A0 (en) Benzo-heterocycles,their preparation and pharmaceutical compositions containing them
IL72422A (en) N6-diarylalkyl adenosines,their preparation and pharmaceutical compositions containing them
IL71481A0 (en) Substituted indeno-pyridazinones,their preparation and pharmaceutical compositions containing them
IL70755A (en) 3-amino-4-cyano-pyridazine derivatives,their preparation and pharmaceutical compositions containing them
IL71419A0 (en) Phenylaminobenzenealkanols,their preparation and pharmaceutical compositions containing them
IL72152A0 (en) 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them
IL72123A0 (en) Substituted phenylalkyl-piperazinyl-and homopiperazinyl-propyl-ureas and-thioureas,their preparation and pharmaceutical compositions containing them
IL72307A0 (en) Pyridinyl-2-pyrimidinamines,their preparation and pharmaceutical compositions containing them
IL71110A0 (en) Azolylmethylcycloalkanes,their preparation and pharmaceutical compositions containing them
IL73278A0 (en) Pharmaceutical compositions containing 1,2-dithiolan derivatives,certain such derivatives and their preparation
IL71661A0 (en) 4-phenyl-tetrahydro-furano-pyridines,their preparation and pharmaceutical compositions containing them
IL65177A (en) Fluoroprostacyclins,their preparation and pharmaceutical compositions containing them
EP0127371A3 (en) 1,n-diaryl-4,5-dihydro-1h-pyrazol-3-amines, compositions containing them and methods for their preparation
PH22848A (en) 3,3-dialkyl- and 3,3,-alkylene-indoline derivatives, pharmaceutical compositions comprising them and their use
IL73075A0 (en) Antihyperlipidemic n-benzoyl-sulfamates,n-benzylsulfamates and benzylsulfonamides,process for the preparation thereof and pharmaceutical compositions containing them
ZA83959B (en) 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them
IL73421A (en) 3-azabicyclo(3,3,1)-6-aminononanes,process for their preparation and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
KB Patent renewed
EXP Patent expired